Executive SummaryPrivately-held carbohydrate pharmaceutical R&D firm, based in Alameda, California, completes two private placements totaling$15.5 mil. The fundings include a $4 mil. equity investment by Lilly that is part of a three-year research agreement announced in January ("The Pink Sheet" Jan. 15, In Brief).
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.